Category - Developments

Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China. The JV will initially target...

BioTuesdays’ Stephen Kilmer joins Titan management, directors and guests at the bell closing ceremony. Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP)...

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week. Probuphine, a subdermal implant...

Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment...

Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines. The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with...

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the “12 Most Important Innovations of the Year” in the health category in Popular Science’s annual Best of...

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic...

3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company’s first step toward validation and approval of...